Alexander KarpAlexander Karp earned $1B in 2024

In 2012, Matthew W. Emmens earned $497.18K in total compensation at Vertex Pharmaceuticals, primarily from $467.51K salary. Most recently sold 10,850 shares in Nov 2011. Led Vertex Pharmaceuticals as CEO for 2 years.

Compensation History

Annual executive compensation data for Matthew W. Emmens, including salary, bonuses, and stock awards.

Year

2012

Total Compensation

$497.18K

Salary

$467.51K

Bonus

$0.00

Other

$29.67K

Salary

$467.51K

Board Justification

The compensation program is designed to attract and motivate talented and experienced individuals, aligning their interests with those of shareholders.

Bonus

$0.00

Board Justification

Mr. Emmens was not eligible for an annual cash bonus for 2012 performance.

Other Compensation

$29.67K

Board Justification

This includes board compensation received after his retirement from employment in May 2012.

Restricted Stock

$0.000 Restricted Stock

Board Justification

Mr. Emmens did not receive any stock grants that vested in 2012.

Performance Metrics

The company's performance rating for 2012 was 'leading', with a score of 90% against its goals.

V

Matthew W. Emmens

Ex-CEO of Vertex Pharmaceuticals

Sector of Economy

Healthcare

CEO of Vertex Pharmaceuticals for

2 years 8 months (May 2009 - Feb 2012)

Previous Experience

CEO of Astra Merck, Inc., and of Shire plc

Holdings

Track Matthew W. Emmens's stock holdings and portfolio value over time.

Total Stock Sold

$988.21K

VRTX

$988.21K

20,585 VRTX shares

What if they kept their stock?

If Matthew W. Emmens didn't sell their stock, today they would have:
Extra VRTX20,585 shares worth $9.41M.
This is 852.5% and $8.42M more than what they got when they sold the stock.

Insider Trading

Matthew W. Emmens's recent stock transactions, purchases, and sales filed with the SEC.

Rivals

Compare Matthew W. Emmens with competitor CEOs and industry peers.